A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia - Regional Cancer Care Associates LLC

Clinical Trials

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia
Locations
Freehold
Howell
Sponsor
Acerta
Protocol Number
ACE-CL-006
Cancer Diagnosis
To Learn More Call
201-510-0910